Name: UMIN ID:
Unique ID issued by UMIN | UMIN000032659 |
---|---|
Receipt number | R000036700 |
Scientific Title | A phase 2 study of KRd(carfilzomib, lenalidomide, dexamethasone) consolidation for newly diagnosed multiple myeloma |
Date of disclosure of the study information | 2018/05/22 |
Last modified on | 2022/01/27 11:30:13 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/05/21 14:59:54 | ||
2 | Update | 2018/05/23 20:13:21 | Recruitment status |
|
3 | Update | 2018/05/24 20:04:32 | Organization Organization |
|
4 | Update | 2018/07/27 13:49:28 | Institutions |
|
5 | Update | 2018/11/19 21:18:53 | Email1 |
|
6 | Update | 2018/11/21 21:41:37 | Organization1 Address1 Tel1 Email1 |
|
7 | Update | 2018/11/22 19:43:09 | Email1 |
|
8 | Update | 2019/05/22 12:32:33 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel Institutions |
|
9 | Update | 2019/05/22 12:39:35 | Date of IRB Last follow-up date |
|
10 | Update | 2019/12/19 20:52:49 | Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
11 | Update | 2019/12/19 21:10:40 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria Target sample size |
|
12 | Update | 2019/12/19 21:13:13 | Last follow-up date |
|
13 | Update | 2019/12/21 14:49:26 | Key inclusion criteria Key exclusion criteria |
|
14 | Update | 2021/06/10 10:59:59 | Email1 |
|
15 | Update | 2021/07/09 19:47:58 | Email1 |
|
16 | Update | 2022/01/27 11:30:13 | Recruitment status |